NIH implants 1st U.S. patient with stem cells to treat AMD

By The Science Advisory Board staff writers

September 1, 2022 -- A National Institutes of Health (NIH) surgical team implanted the first U.S. patient with a patch of tissue made from stem cells to treat advanced “dry” age-related macular degeneration (AMD). Also known as geographic atrophy, dry AMD is a leading cause of vision loss among older Americans and currently has no treatment, according to the NIH.

The clinical trial uses replacement tissues from patient-derived induced pluripotent stem (iPS) cells, developed by the Ocular and Stem Cell Translational Research Section team at NIH with support from Fujifilm Cellular Dynamics and Opsis Therapeutics. The clinical-grade manufacturing of the cell therapy was performed at NIH's Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center.

The culmination of 10 years of research and development, the patient's blood cells were converted to iPS cells, which were programmed to become retinal pigment epithelial (RPE) cells. RPE cells nourish and support light-sensing photoreceptors in the retina and in AMD, the loss of RPE leads to the loss of photoreceptors, causing vision loss.

Loss of protective protein linked to age-related changes in the eye
A study in mice has shown that the loss of a protein that protects retinal support cells may drive aging-associated diseases of the retina such as macular...
Optogenetic gene therapy provides hope for retinitis pigmentosa patients
Optogenetic therapy bypasses traditional methods of repairing defective photoreceptors in the eye by targeting other retinal cells. Recently, three examples...
Janssen acquires rights to AMD gene therapy
Janssen Pharmaceuticals has acquired rights of Hemera Biosciences' investigational gene therapy, HMR59, a one-time, outpatient, intravitreal injection...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter